DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study

被引：0

作者：

Shiao, Hui-Yi ^{[1
]}

Hsu, Tsu-An John ^{[1
]}

Chen, Chiung-Tong ^{[1
]}

Yeh, Teng-Kuang ^{[1
]}

Hsieh, Hsing-Pang ^{[1
]}

机构：

[1] Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Zhunan 350, Miaoli County, Taiwan

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2014年 / 247卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

315-MEDI

引用

页数：1

共 50 条

[1] Development drug candidate targeting EGFR kinase: DBPR112
Sun, Hsu-Yi
Hsu, John T. A.
Chen, Chiung-Tong
Yeh, Teng-Kuang
Pan, Shiow-Lin
Chao, Yu-Sheng
Hsieh, Hsing-Pang
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
[2] Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma
Shiao, Hui-Yi
Hsu, Tsu-An
Lin, Wen-Hsing
Yang, Tsong-Toh
Hsieh, Hui-Fang
Chen, Chiung-Tong
Yeh, Teng-Kuang
Hsieh, Hsing-Pang
[J]. CANCER RESEARCH, 2014, 74 (19)
[3] A DEVELOPMENT DRUG CANDIDATE TARGETING EGFR KINASE FOR LUNG CANCER: DBPR112
Hsieh, Hsing-Pang
Shiao, Hui-Yi
Chen, Chiung-Tong
Yeh, Teng-Kuang
[J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S779 - S780
[4] Discovery and Development of DBPR112 as a Clinical Candidate: A Novel EGFR Inhibitor for Non-small Cell Lung Cancer
Hsieh, Hsing-Pang
Hsu, John T. -A.
Yeh, Teng-Kuang
Chen, Chiung-Tong
[J]. CANCER SCIENCE, 2018, 109 : 739 - 739
[5] Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor
Stuart, Darrin D.
Li, Nanxin
Poon, Daniel J.
Aardalen, Kimberly
Kaufman, Susan
Merritt, Hanne
Salangsang, Fernando
Lorenzana, Edward
Li, Allen
Ghoddusi, Majid
Caponigro, Giordano
Sun, Frank
Kulkarni, Swarupa
Kakar, Shefali
Turner, Nancy
Zang, Richard
Tellew, John
Pryer, Nancy
[J]. CANCER RESEARCH, 2012, 72
[6] Preclinical activity of the first reversible, potent and selective inhibitor of EGFR exon 20 insertions.
Siegel, Franziska
Siegel, Stephan
Graham, Keith
Kaplan, Bethany
Petersen, Kirstin
Boemer, Ulf
Eberspaecher, Uwe
Korr, Daniel
Moenning, Ursula
Suelzle, Detlev
Schroeder, Jens
Prinz, Florian
Zitzmann-Kolbe, Sabine
Karsli-Uzunbas, Gizem
Lewis, Timothy
Hermsen, Mario
Cherniack, Andrew
von Nussbaum, Franz
Eis, Knut
Meyerson, Matthew
Greulich, Heidi
[J]. CANCER RESEARCH, 2021, 81 (13)
[7] The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC
Elamin, Y.
Robichaux, J.
Lam, V.
Tsao, A.
Lu, C.
Blumenschein, G.
Kurie, J.
Brahmer, J.
Li, S.
Chen, T.
Estrada-Bernal, A.
Truini, A.
Nilsson, M.
Le, A.
Tan, Z.
Zhang, S.
Doebele, R.
Politi, K.
Yang, Z.
Liu, S.
Wong, K.
Heymach, J.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1776 - S1776
[8] Clinical candidate DBPR112: A novel epidermal growth factor receptor inhibitor as a promising treatment for non-small cell lung cancer
Hsieh, Hsing-Pang
Chang, Jang-Yang
Kuo, Ching-Chuan
Hsu, John
[J]. CANCER RESEARCH, 2018, 78 (13)
[9] Discovery of clinical candidate DBPR112, a furanopyrimidine-based epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer
Hsieh, H-P.
Chang, J-Y.
Yeh, C-T.
Lin, S-Y.
Ke, Y-Y.
Lin, W-H.
Hsu, T-A.
Wu, S-Y.
Yeh, T-K.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 789 - 789
[10] Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer
Lin, Shu-Yu
Hsu, Yung Chang
Peng, Yi-Hui
Ke, Yi-Yu
Lin, Wen-Hsing
Sun, Hsu-Yi
Shiao, Hui-Yi
Kuo, Fu-Ming
Chen, Pei-Yi
Lien, Tzu-Wen
Chen, Chun-Hwa
Chu, Chang-Ying
Wang, Sing-Yi
Yeh, Kai-Chia
Chen, Ching-Ping
Hsu, Tsu-An
Wu, Su-Ying
Yeh, Teng-Kuang
Chen, Chiung-Tong
Hsieh, Hsing-Pang
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (22) : 10108 - 10123

← 1 2 3 4 5 →